5.51
+0.13(+2.42%)
Currency In USD
| Previous Close | 5.38 |
| Open | 5.39 |
| Day High | 5.63 |
| Day Low | 5.22 |
| 52-Week High | 13 |
| 52-Week Low | 3 |
| Volume | 22,504 |
| Average Volume | 59,271 |
| Market Cap | 37.13M |
| PE | -0.58 |
| EPS | -9.46 |
| Moving Average 50 Days | 5.7 |
| Moving Average 200 Days | 4.89 |
| Change | 0.13 |
If you invested $1000 in Generation Bio Co. (GBIO) since IPO date, it would be worth $22.32 as of December 11, 2025 at a share price of $5.51. Whereas If you bought $1000 worth of Generation Bio Co. (GBIO) shares 3 years ago, it would be worth $117.48 as of December 11, 2025 at a share price of $5.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Generation Bio Announces Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 05, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and marketab
Generation Bio Announces CEO Transition
GlobeNewswire Inc.
Oct 22, 2025 8:05 PM GMT
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 12, 2025 8:05 PM GMT
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T c